Compassionate use of gene therapies raises ethical, commercial quandaries
Why compassionate use of gene therapies raises commercial and ethical challenges
No matter how quickly gene therapies are developed, there will always be a gap between the news that a product may radically alter the course of a disease and the drug’s approval. Like other investigational drugs for unmet serious conditions, that gap fuels requests for pre-approval access. The ethical and commercial quandaries associated with compassionate use of gene therapies are more challenging than those posed by most medicines.
The first cohort of gene therapies is targeted at rare diseases, and many are destined for patients with no alternatives who face irreversible loss of function or disease progression that will not wait for even an accelerated drug development timeline...